Opna Bio is targeting master regulators to advance the treatment of cancer. These include OPN-6602, a best-in-class EP300/CBP inhibitor, currently in clinical development for treatment of multiple myeloma patients.
EXPLORE
Hanahan et al, November 2022
Upregulation of the neuronal fragile-X multifunctional RNA-binding protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity
Read MoreOPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma
Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies
